Skip to content
Screener

Castle Biosciences CSTL Business Segments — Interest Expense, Nonoperating

Similar metrics at other companies

Booking Holdings Inc. logo
BKNGReportable Segment — Interest Expense, Nonoperating
$253M-61.0%
DocuSign logo
DOCUReportable Segment — Interest Expense, Nonoperating
$636.5K+64.3%
Intuitive Machines, Inc. logo
LUNRReportable Segment — Interest Expense, Nonoperating
$4.89M+18,688%
Andersen Group logo
ANDGReportable Segment — Interest Expense, Nonoperating
$6.23M+4,259%
Opendoor Technologies Inc logo
OPENReportable Segment — Interest Expense, Nonoperating
$23M-30.3%
VGN
VGNTReportable Segment — Interest Expense, Nonoperating
$5M+150%

Other financials

Income statement

See full
Revenue$83.7M-4.9%
Gross profit$63.1M-11.8%
Operating income-$18.4M+34.1%
Net income-$14.5M+43.8%
EPS (diluted)-$0.49+45.6%

Balance sheet

See full
Cash & equivalents$63.8M-28.9%
Total debt$36.7M+42.1%
Total equity$461.4M+4.8%
Total assets$547.8M+9.2%

Cash flow

See full
Operating cash flow-$22.1M-267%
CapEx$12.5M+163%
Free cash flow-$34.6M-221%

Valuation

See full
Market cap$978.5M+76.1%
Enterprise value$951.46M+86.2%
P/S2.9×+1.3×

Profitability

See full
Gross margin77.9%-4.1pp
Operating margin-9.8%-30.8pp
Net margin-3.8%-10.2pp
FCF margin1.3%-10.7pp

Returns & leverage

See full
Return on equity-2.8%-10.6pp
Debt / equity0.1×0.0×
Current ratio6.7×-2.6×

Where this comes from

Reported directly by Castle Biosciences in its filing.

Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.

The source filing: Castle Biosciences’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 4:09 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-031263
Line itemThree Months Ended March 31, 20262025
Operating loss(18,407)(27,928)
Interest income2,5453,099
Net gains (losses) on equity securities2,022(1,425)
Interest expense(134)(17)
Other loss(439)
Loss before income taxes(14,413)(26,271)
Income tax expense (benefit)109(423)
Net loss$(14,522)$(25,848)

Item 1. Financial Statements.

FAQ

What is Castle Biosciences's business segments — interest expense, nonoperating?
Castle Biosciences (CSTL) reported business segments — interest expense, nonoperating of $134K in Q1 2026.
How has Castle Biosciences's business segments — interest expense, nonoperating changed year-over-year?
Castle Biosciences's business segments — interest expense, nonoperating increased by 688.2% year-over-year, from $17K to $134K.
What is the long-term trend for Castle Biosciences's business segments — interest expense, nonoperating?
Over 3 years (2022 to 2025), Castle Biosciences's business segments — interest expense, nonoperating has grown at a 71.7% compound annual growth rate (CAGR), from $17K to $86K.
What does business segments — interest expense, nonoperating mean?
Captures the costs associated with servicing debt or other financial obligations that are not directly tied to core operating activities. This metric is used to assess the financial leverage and the cost of capital for the segment.

Ask your AI about Castle Biosciences's business segments — interest expense, nonoperating.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude